CymaBay Therapeutics Inc said on Monday it was scrapping two mid-stage studies testing its lead drug for two types of liver diseases after observing "atypical" findings in one of the trials, sending its shares down 79% in premarket trading. Reuters Health News

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Time limit is exhausted. Please reload CAPTCHA.